Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) has noted that its AI-powered technology, powering the Safe Entry Station was featured in a major Indonesian newspaper on March 27, confirming the effectiveness of the technology as well as its potential for healthcare.
Safe Entry uses a fully patented system to rapidly and autonomously screen for individuals' key vitals. It is a non-invasive, contactless solution that uses AI-powered technology to assess multiple symptoms and indicators, including temperature, heart rate, and respiratory rate, to quickly identify potential health risks.
The University of Raharja conducted testing and validation on over 2,000 individuals using Safe Entry and is now working with the government to identify solutions for the healthcare sector while working towards the approval of Safe Entry as a medical device in Indonesia.
READ: Predictmedix expands its non-invasive AI-powered impairment detection technology across specific verticals
"We are incredibly honoured to receive international recognition along with an independent third-party news article for our Safe Entry solution in Indonesia, a country where our technology is uniquely positioned to make a significant impact,” Dr Rahul Kushwah, COO at Predictmedix said in a statement.
“We have had 400 more individuals screened by our technology since our last announcement of 1600 individuals participating in third-party tech validation in Indonesia. With a staggering 2,500 hospitals across the country, there is an urgent need for a comprehensive risk management solution like Safe Entry in every triage and hospital. We are proud to be collaborating with the prestigious University of Raharja and the Indonesian government to bring Safe Entry to the forefront of healthcare innovation in Indonesia," he added.
The company also announced that it has granted incentive stock options to consultants of the company to purchase an aggregate of 600,000 common shares with an exercise price of $0.15 per common share expiring four years from the date of grant.
Predictmedix is an emerging provider of rapid health screening and remote patient care solutions globally.
Contact the author at jon.hopkins@proactiveinvestors.com